Search results
General Partner. Wellesley. Eric, who joined Ampersand in 2013, has 18 years of middle market healthcare investment experience. Eric’s current and past board seats include ALPCO, Biologos, Biosynth, CutisPharma, Genoptix, iuvo Biosciences, LakePharma, Leinco Technologies, Nexelis, Nexcelom Biosciences, P95 and Resolian (formerly Alliance Pharma).
Nov 17, 2021 · Eric Lev, General Partner at Ampersand and incoming Board member of Leinco, added, “Leinco is a tremendous fit with Ampersand’s investment strategy of supporting growth-oriented life science and healthcare organizations with established leadership positions in specialty segments of the market.
Mar 19, 2024 · Eric Lev adds, "The investment in Biologos aligns well with Ampersand's strategy of supporting growth-oriented life science organizations with a history of product innovation and customer...
Jun 25, 2021 · Eric Lev, General Partner of Ampersand Capital Partners, added, "When Ampersand began its partnership with co-owners Peter Li and CTO & Founder Jean Qiu about three years ago, we saw promise in Nexcelom's technology and believed we could help the company leverage its unique solutions to expand its presence in therapeutics development and ...
Eric Lev Overview. Update this profile. Firm. Ampersand Capita... Primary Position. General Partner. Primary Industry. Healthcare. Active Board Seats. 4. Med. Deal Size. Med. Valuation. General Information. Biography. Mr. Eric Lev serves as a General Partner at Ampersand Capital Partners.
Eric Lev is known for One on One (2001), The Game (2006) and Legends of Chamberlain Heights (2016). Add photos, demo reels. Add to list. More at IMDbPro. Contact info. Agent info. Known for. One on One. 7.1. TV Series. Producer. 2004–2006 • 44 eps. The Game. 6.8. TV Series. Producer. 2008–2009 • 22 eps. Legends of Chamberlain Heights. 4.9.
Eric Lev General Information. Biography. Mr. Eric Lev serves as General Partner at Ampersand Capital Partners. He serves as Board Member at Interpace Biosciences. Mr. Lev has more than 17 years of experience in life science investing.
